To be an international destination center that develops and delivers innovative and personalized cancer therapies.
ITOR is a major pillar of translational cancer research at Prisma Health. The efforts of ITOR include a phase I Clinical Research Unit, a Biorepository Services platform, and proteomics & genomics capabilities.
ITOR advances cancer care on multiple levels, facilitating pioneering research as well as clinical care delivery. ITOR is committed to “translational” medicine, which is a branch of medical research that forges a direct link between basic research and patient care. In the case of drug therapies, translational medicine refers to the “translation” of basic research into beneficial drug treatments for patients.
ITOR focuses on discovering and developing drugs that help people who have cancer.